Subtypes in monosymptomatic nocturnal enuresis. II

Area of Science:

• Pediatric endocrinology
• Sleep medicine
• Urology

Background:

• Monosymptomatic nocturnal enuresis (MNE) exhibits low lasting cure rates with current treatments like alarms, imipramine, and desmopressin.
• Insufficient understanding of MNE pathophysiology hinders effective treatment development.
• Arginine vasopressin (AVP) levels in nocturnal enuresis are a unique research area for identifying patients who may benefit from desmopressin therapy.

Purpose of the Study:

• To investigate the role of arginine vasopressin (AVP) levels in monosymptomatic nocturnal enuresis (MNE).
• To explore the potential of desmopressin substitution therapy for specific MNE patient subgroups.
• To examine the link between circadian rhythm disturbances, nocturnal urine output, and AVP production in MNE.

Main Methods:

• Review of existing research on alarm, imipramine, and desmopressin treatments for MNE.
• Analysis of studies focusing on arginine vasopressin (AVP) levels in relation to nocturnal enuresis.
• Evaluation of pre-clinical data on melatonin's role in AVP regulation and sleep/wake cycles.

Main Results:

• Current MNE treatments (alarm, imipramine, desmopressin) report cure rates of 43%, 17%, and 22%, respectively.
• Low nocturnal AVP production coupled with high nocturnal urine output may indicate a circadian rhythm disturbance.
• Pre-clinical evidence suggests melatonin influences both endogenous AVP and the sleep/wake cycle.

Conclusions:

• Further research into AVP levels and circadian rhythms is crucial for understanding MNE.
• Identifying MNE subgroups based on AVP levels could optimize desmopressin therapy.
• Melatonin's potential role in regulating AVP and sleep warrants further investigation for MNE treatment.